Ocular Therapeutix, Inc.

OCUL

$11.37

Name : Ocular Therapeutix, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $2,423,159,296.00

EPSttm : -1.43

Ocular Therapeutix, Inc.

$11.37

3.77%

$0.446

Float Short %

5.67

Margin Of Safety %

Put/Call OI Ratio

0.47

EPS Next Q Diff

-1.84

EPS Last/This Y

-0.21

EPS This/Next Y

-0.05

Price

11.83

Target Price

24.62

Analyst Recom

1.08

Performance Q

6.87

Relative Volume

0.78

Beta

0.93

Ticker: OCUL

17 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-08	OCUL	16.12	0.41	0.17	79322
2025-12-09	OCUL	15.94	0.40	0.69	83577
2025-12-10	OCUL	15.4	0.40	1.98	84310
2025-12-11	OCUL	14.66	0.45	0.40	89284
2025-12-12	OCUL	14.57	0.45	1.52	90955
2025-12-15	OCUL	14.16	0.43	0.67	90369
2025-12-16	OCUL	14.39	0.43	1.25	90518
2025-12-17	OCUL	13.72	0.44	3.00	92006
2025-12-18	OCUL	12.98	0.47	0.08	95384
2025-12-19	OCUL	12.55	0.46	0.12	96767
2025-12-22	OCUL	13	0.47	0.34	87026
2025-12-23	OCUL	12.75	0.48	0.05	88076
2025-12-26	OCUL	12.56	0.46	0.01	91183
2025-12-29	OCUL	12.29	0.46	0.32	91062
2025-12-30	OCUL	12.2	0.46	0.01	92038
2025-12-31	OCUL	12.13	0.46	0.05	92400
2026-01-02	OCUL	11.82	0.47	0.39	93008
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

17 items 1 of 1

17 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-08	OCUL	16.11	-16.1	-	-1.42
2025-12-09	OCUL	15.95	-16.1	-	-1.42
2025-12-10	OCUL	15.40	-16.1	-	-1.42
2025-12-11	OCUL	14.66	-16.1	-	-1.42
2025-12-12	OCUL	14.56	-16.1	-	-1.42
2025-12-15	OCUL	14.17	-16.1	-	-1.42
2025-12-16	OCUL	14.17	-16.1	-	-1.43
2025-12-17	OCUL	13.73	-16.1	-	-1.43
2025-12-18	OCUL	12.98	-16.1	-	-1.43
2025-12-19	OCUL	12.55	-16.1	-	-1.43
2025-12-22	OCUL	12.94	-16.1	-	-1.43
2025-12-23	OCUL	12.73	-16.1	-	-1.43
2025-12-26	OCUL	12.57	-16.1	-	-1.43
2025-12-29	OCUL	12.30	-16.1	-	-1.43
2025-12-30	OCUL	12.20	-16.1	-	-1.43
2025-12-31	OCUL	12.13	-16.1	-	-1.43
2026-01-02	OCUL	11.83	-16.1	-	-1.43
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

17 items 1 of 1

17 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-08	OCUL	-0.44	18.54	7.05
2025-12-09	OCUL	-0.44	18.54	7.05
2025-12-10	OCUL	-0.44	18.54	6.23
2025-12-11	OCUL	-0.44	18.54	6.22
2025-12-12	OCUL	-0.44	18.54	6.22
2025-12-15	OCUL	-0.44	19.12	6.22
2025-12-16	OCUL	-0.44	19.12	6.22
2025-12-17	OCUL	-0.44	19.12	6.22
2025-12-18	OCUL	-0.44	19.12	6.22
2025-12-19	OCUL	-0.44	19.12	6.22
2025-12-22	OCUL	-0.44	19.12	6.22
2025-12-23	OCUL	-0.44	19.12	6.22
2025-12-26	OCUL	-0.44	19.12	5.67
2025-12-29	OCUL	-0.44	19.13	5.67
2025-12-30	OCUL	-0.44	19.13	5.67
2025-12-31	OCUL	-0.44	19.13	5.67
2026-01-02	OCUL	-0.44	19.13	5.67
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

17 items 1 of 1

Last Quarter Act. EPS

1.5

Avg. EPS Est. Current Quarter

-0.34

Avg. EPS Est. Next Quarter

-0.34

Insider Transactions

-0.44

Institutional Transactions

19.13

Beta

0.93

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-90.6

Target Price

24.62

P/E

Forward P/E

PEG

P/S

45.15

P/B

8.01

P/Free Cash Flow

EPS

-1.44

Average EPS Est. Cur. Y

-1.43

EPS Next Y. (Est.)

-1.48

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-447.58

Relative Volume

0.78

Return on Equity vs Sector %

-124

Return on Equity vs Industry %

-108.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

Ocular Therapeutix, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 274

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

stock quote shares OCUL – Ocular Therapeutix, Inc. Stock Price stock today

news today OCUL – Ocular Therapeutix, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch OCUL – Ocular Therapeutix, Inc. yahoo finance google finance

stock history OCUL – Ocular Therapeutix, Inc. invest stock market

stock prices OCUL premarket after hours

ticker OCUL fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: OCUL

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y